SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization may be delayed.</u>

<u>Drug Requested</u>: (Select drug below)

| □ Difficid ® (fidaxomicin) | □ Dificid® (fidaxomicin) suspension |
|---|---|
| FOR THE APPROVAL OF RECURRENT CLOS | STRIDIUM DIFFICILE-ASSOCIATED DIARRHEA |
| MEMBER & PRESCRIBER INFORMA | TION: Authorization may be delayed if incomplete. |
| Member Name: | |
| Member Sentara #: | Date of Birth: |
| Prescriber Name: | |
| Prescriber Signature: | Date: |
| Office Contact Name: | |
| Phone Number: | Fax Number: |
| DEA OR NPI #: | |
| DRUG INFORMATION: Authorization may | be delayed if incomplete. |
| Drug Form/Strength: | |
| | Length of Therapy: |
| Diagnosis: | ICD Code, if applicable: |
| Weight: | Date: |
| Authorization for medication will only be approved for the following course of therapy: | |
| Adult Dosing | Dificid 200 mg twice daily for 10 days |
| Infants ≥ 6 months and Children ≤ 8 years old | 16 mg/kg/dose twice daily for 10 days; maximum dose: 200 mg/dose 4 to <7 kg: Oral: Oral suspension: 80 mg twice daily for 10 days. 7 to <9 kg: Oral: Oral suspension: 120 mg twice daily for 10 days. 9 to <12.5 kg: Oral: Oral suspension: 160 mg twice daily for 10 days. ≥12.5 kg: Oral: Oral suspension, tablets: 200 mg |

twice daily for 10 days.

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

| | Medication is being requested to complete the length of therapy started in an inpatient setting |
|------------|--|
| | Days of therapy, and quantity required for completion: daystablets/mL |
| | OR |
| Al | ll of the following criteria must be met: |
| | Medication must be prescribed by a hospitalist, internist or in consultation with ONE of the following (please note): |
| | ☐ Infectious Disease Specialist ☐ Gastroenterologist Specialist |
| | AND |
| | Member is 6 months of age or older |
| | AND |
| | FOR PEDIATRIC PATIENTS: Member's weight must be submittedkg |
| | AND |
| | Member must have had trial and failure of vancomycin 125 mg by mouth four times daily for 10 days, or prolonged taper and pulsed vancomycin, for an initial C. difficile episode treatment (claim must be documented in pharmacy paid claims) |
| | Date of initial C. difficile infection episode: |
| | AND |
| | Member must be experiencing another infection following an initial infection episode of C. difficile , or symptoms from initial infection did not improve after initial treatment |
| | AND |
| | Submission of positive stool toxin test for the <u>CURRENT</u> infection episode is required (must attach lab results) |
| | |
| | |
| ** | Use of samples to initiate therapy does not meet step edit/preauthorization criteria.** |
| <u>Pre</u> | vious therapies will be verified through pharmacy paid claims or submitted chart notes. |

^{*}Approved by Pharmacy and Therapeutics Committee: \(\frac{10/20/2011}{20/2018}\); \(\frac{6/21/2018}{2019}\); \(\frac{6/21/2018}{2020}\); \(\frac{7/21/2020}{2020}\); \(\frac{11/2020}{2020}\); \(\frac{6/2020}{2020}\); \(\frac{11/2020}{2020}\); \(\frac{6/30/2021}{2020}\); \(\frac{8/19/2022}{2020}\); \(\frac{8/1